S Jerwood1, J Cohen. 1. Department of Microbiology and Infectious Diseases, Royal Sussex County Hospital, Eastern Road, Brighton BN2 5BE, UK.
Abstract
OBJECTIVES: Epidemiological studies of statins have suggested a link between statin therapy and a decreased risk of sepsis. It has been proposed that the mechanism underlying this apparent protective effect of statins relates to their known immunomodulatory and anti-inflammatory effects. The aim of this study was to explore the antimicrobial effect of statins. METHODS: Simvastatin (Merck) and fluvastatin (Novartis) were both tested against six of each of methicillin-susceptible and -resistant Staphylococcus aureus (MSSA + MRSA), and vancomycin-sensitive and -resistant enterococci (VSE + VRE) using a microtitre dilution method. The test was repeated five times for both statins against all 24 isolates. Vancomycin, linezolid and propranolol were used as controls, as appropriate. RESULTS AND DISCUSSION: Simvastatin showed a significant antimicrobial effect against MSSA (mean MIC 29.2 mg/L) and to a lesser extent against MRSA (mean MIC 74.9 mg/L). Fluvastatin had a significantly less marked antimicrobial effect. Propranolol showed no antimicrobial effect. Simvastatin has a considerable antimicrobial effect in vitro and further testing of it is warranted.
OBJECTIVES: Epidemiological studies of statins have suggested a link between statin therapy and a decreased risk of sepsis. It has been proposed that the mechanism underlying this apparent protective effect of statins relates to their known immunomodulatory and anti-inflammatory effects. The aim of this study was to explore the antimicrobial effect of statins. METHODS:Simvastatin (Merck) and fluvastatin (Novartis) were both tested against six of each of methicillin-susceptible and -resistant Staphylococcus aureus (MSSA + MRSA), and vancomycin-sensitive and -resistant enterococci (VSE + VRE) using a microtitre dilution method. The test was repeated five times for both statins against all 24 isolates. Vancomycin, linezolid and propranolol were used as controls, as appropriate. RESULTS AND DISCUSSION: Simvastatin showed a significant antimicrobial effect against MSSA (mean MIC 29.2 mg/L) and to a lesser extent against MRSA (mean MIC 74.9 mg/L). Fluvastatin had a significantly less marked antimicrobial effect. Propranolol showed no antimicrobial effect. Simvastatin has a considerable antimicrobial effect in vitro and further testing of it is warranted.
Authors: Ohn A Chow; Maren von Köckritz-Blickwede; A Taylor Bright; Mary E Hensler; Annelies S Zinkernagel; Anna L Cogen; Richard L Gallo; Marc Monestier; Yanming Wang; Christopher K Glass; Victor Nizet Journal: Cell Host Microbe Date: 2010-11-18 Impact factor: 21.023
Authors: Eric M Mortensen; Brandy Nakashima; John Cornell; Laurel A Copeland; Mary Jo Pugh; Antonio Anzueto; Chester Good; Marcos I Restrepo; John R Downs; Christopher R Frei; Michael J Fine Journal: Clin Infect Dis Date: 2012-08-23 Impact factor: 9.079
Authors: Erin M Burns; Lisa K Smelser; Jenny E Then; Traci E Stankiewicz; Michael Kushdilian; Susan A McDowell; Heather A Bruns Journal: Curr Pharm Biotechnol Date: 2013 Impact factor: 2.837
Authors: Tricia A Van Laar; Camaron Hole; S L Rajasekhar Karna; Christine L Miller; Robert Reddick; Floyd L Wormley; J Seshu Journal: Microbes Infect Date: 2016-03-16 Impact factor: 2.700